Andrew Davies
A5069477380- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Total Knee Arthroplasty Outcomes
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Knee injuries and reconstruction techniques
- Immune Response and Inflammation
- Chronic Myeloid Leukemia Treatments
- T-cell and B-cell Immunology
- Toxin Mechanisms and Immunotoxins
- Orthopaedic implants and arthroplasty
- Hematopoietic Stem Cell Transplantation
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
University of Southampton
2016-2025
Guy's and St Thomas' NHS Foundation Trust
2013-2025
Queen Mary University of London
1968-2025
NIHR CRUK Experimental Cancer Medicine Centre
2016-2024
Cancer Research UK
2015-2024
University Hospital Southampton NHS Foundation Trust
2013-2024
King's College London
2017-2024
National Health Service
2016-2024
Lancashire Teaching Hospitals NHS Foundation Trust
2020-2024
National Institute for Health Research
2021-2023
Patients with follicular lymphoma may survive for periods of less than 1 year to more 20 years after diagnosis. We used gene-expression profiles tumor-biopsy specimens obtained at diagnosis develop a molecular predictor the length survival.Gene-expression profiling was performed on 191 biopsy from patients untreated lymphoma. Supervised methods were discover expression patterns associated survival in training set 95 specimens. A constructed these genes and validated an independent test 96...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.
Since the publication of Revised European-American Classification Lymphoid Neoplasms in 1994, subsequent updates classification lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently made characterization malignancies immune system, with many new insights provided by genomic studies. They led this proposal. We followed same process...
The monocarboxylate transporter MCT4 mediates lactic acid efflux from most tissues that are dependent on glycolysis for their ATP production. Here we demonstrate expression of mRNA and protein was increased >3-fold by a 48-h exposure to 1% O2, whereas MCT1 not increased. effect mimicked CoCl2 (50 μm), suggesting transcriptional regulation hypoxia-inducible factor 1α (HIF-1α). predicted promoters human MCT1, MCT2, were cloned into the pGL3 vector shown be active (luciferase luminescence)...
Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy obinutuzumab-based previously untreated advanced-stage
To study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL) in patients with follicular (FL).From 1972 1999, 325 were diagnosed FL at St Bartholomew's Hospital (London, United Kingdom). With a median follow-up 15 years, progression occurred 186 and biopsy-proven 88 325. The overall repeat biopsy rate was 70%.The risk histologic (HT) by 10 years 28%, HT not yet having been observed after 16.2 years. higher advanced stage (P = .02), high-risk Follicular...
A single thymus lobe from a neonatal donor has the capacity to restore primary immunological competence thymectomized syngeneic radiation chimaera. If cytologically marked graft is used fate of introduced cells following antigenic stimulation may be studied. Thymus-derived can found in spleen and lymph-nodes such mice furthermore there transient but well-defined increase proportion these dividing an injection sheep red blood or application skin homograft 30 days after irradiation grafting....
Purpose Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence subgroup with poor prognosis phenotypic proximity to Burkitt well known. Conventional cytogenetics identifies some patients rearrangements MYC BCL2 and/or BCL6 (double-hit lymphomas) who are increasingly treated more intensive chemotherapy, but biologically coherent clinically useful definition this group required. Patients Methods We defined molecular high-grade (MHG) by applying gene...
Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell origin, corresponding germinal centre or activated B cell. We aimed investigate whether adding bortezomib standard therapy could improve outcomes in patients with these subtypes.
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) patients relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients Methods CD20+ DLBCL age ≥ 18 years who had experienced their first relapse were to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like treatment randomly assigned between...
Abstract Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights these studies have been intrinsic limitations in study design. Here we present PROSECO prospective observational ( NCT04858568 ) on 457 patients lymphoma that received two or three vaccine doses. We show undetectable humoral responses following doses 52% undergoing active anticancer treatment. Moreover, 60% anti-CD20 therapy had antibodies...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone...
Abstract CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost Barrett’s esophagus (BE) esophageal adenocarcinoma (EAC). How other gene co-deletions affect EAC evolution remains understudied. We explored the effects of loss EACs cancer progressor non-progressor BEs with matched genomic, transcriptomic clinical data. Despite its driver role, BE prevents initiation by counterselecting subsequent TP53 alterations. predict poor patient survival but not through...
Translocation of monocarboxylate transporters MCT1 and MCT4 to the plasma membrane requires CD147 (basigin) with which they remain tightly associated. However, importance for MCT activity is unclear. are both inhibited by cell-impermeant organomercurial reagent p-chloromercuribenzene sulfonate (pCMBS). Here we demonstrate site-directed mutagenesis that removal all accessible cysteine residues on does not prevent this inhibition. pCMBS treatment cells abolished co-immunoprecipitation enhanced...